ATELERIX LIFE SCIENCES INC

Charlottesville, VA · Founded 2020 · Biotech · Private

ATLX-0199, a thiol-based small molecule therapeutic reversing opioid-induced side effects

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · atelerixlifesciences.com

Sector: Biotech
Headquarters: Charlottesville, VA
Founded: 2020
Latest Form D: $650K, Oct 2022
Total capital: $4.4M

Federal grants: $3.7M; 3 awards · 2022–2023; Rank in peer group#83 of 326
Private capital raised: $650K; 1 Form D · last Oct 2022; 49 months since last filing
Federal contracts: $68K; 1 award · Health and Human S; Rank in Biotech#345 of 4373
Granted patents: None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

Latest events

Sep 2023Federal contractHealth and Human S · Atelerix - The Overall Objective Of This Contract Is To Plan And Execute A Phase 1A Clinical Trial (hereafter Referred To As The ?phase 1A Trial?) Of The Novel Small Molecule ATLX-0199 In 30 Normal Healthy Subjects. The Goal Of The Clinical Trial Is$68K
Aug 2023Federal grantHealth and Human S · Phase II · Development of Sudaxine for the Treatment of Opioid Induced Respiratory Depression (OIRD) in the Peri-operative Hospital Setting$928K
Oct 2022Private capital raisedForm D · SEC · 1st filing$650K
Sep 2022Federal grantHealth and Human S · Phase II · Development of Sudaxine for the Treatment of Opioid Induced Respiratory Depression (OIRD) in the Peri-operative Hospital Setting$1.8M
Sep 2022Federal grantHealth and Human S · Phase II · Development of Sudaxine for the Treatment of Opioid Induced Respiratory Depression (OIRD) in the Peri-operative Hospital Setting$909K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

<1months

from ATELERIX LIFE SCIENCES INC’s first federal award to its first private round.

First federal award · Sep 2022: Health and Human S · $909K
First Form D · Oct 2022: $650K · 1st Form D
Awards before first raise: 2 awards

An association in public records, not a cause or a prediction.

Standing among 326 peers

Line = median

Biotech · Molecule

Federal grants#83 · top 25%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings

David KalergisExecutive Officer, Director, PromoterNamed in SEC Form D filings
Peter Barton HuttDirectorNamed in SEC Form D filings
William AkridgeDirectorNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

Agios PharmaceuticalsSimilar federal contract value in Biotech · $73K in contracts
BIOLYTIC LAB PERFORMANCE, INC.Similar federal contract value in Biotech · $72K in contracts
ARDELYX, INC.Similar federal contract value in Biotech · $72K in contracts
Abpro CorpSimilar federal contract value in Biotech · $66K in contracts
RETROTHERAPY, LLCSimilar federal contract value in Biotech · $65K in contracts
CELLULAR RESEARCH, INC.Similar federal contract value in Biotech · $63K in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.